

for Alternative Approaches to Animal Testing

INVITATION "EPAA INDUSTRY MEMBERS FORUM" 8 JUNE 2009

Realistic evaluation of the impact that EPAA has had to date

Dear Sir/Madam,

As announced earlier, we are pleased to invite you to this year's

EPAA Industry Members Forum

on 8 June 2009 - 10h00 to 15h00

at the Sheraton Brussels Airport Hotel (<u>http://www.sheratonbrusselsairport.be</u>)

This is the annual opportunity for all INDUSTRY members of the EPAA to meet, discuss openly about the progress, the challenges ahead and check together on the direction.

Particularly, the objective of this year's Forum is to make a realistic assessment of the impact that EPAA has had to date (either directly or indirectly) and discuss what are the actions companies see as priorities as well as how to make further progress in the future in the light of current legislative, institutional and economic changes.

We would therefore like to encourage participation of all EPAA member companies and supporting associations, including working group experts, company contact persons, Heads of safety groups, 3Rs experts and public affairs specialists from industry.

You will find attached the Programme of the Forum.

The attendance reply form is also attached. For logistic reasons, may we ask you to complete it and return to the attention of Irene Manou at the latest <u>by 27th May</u>.

We very much look forward to meeting you at the Members Forum on 8th June.

Yours sincerely,

Odile de Silva Chairperson of the EPAA Industry Steering Committee (Director European Scientific Affairs, R&D, L'Oréal)

EPAA Industry Secretariat Avenue Herrmann-Debroux 15 B, B-1160 Brussels, Belgium

e-mail: irene.manou@epaaind.eu



Realistic evaluation of the impact that EPAA has had to date

8 June 2008 - 10:15 to 15:00

Sheraton Hotel Brussels National Airport - BELGIUM

Programme

10:00	Registration and coffee	
10:15	Introduction Objectives of the meeting Conclusions from 2008 forum and follow up	Odile de Silva ISC Chair, L'Oreal
10:25	 Achievements and gaps (session 1) Mapping 3Rs In house methods and research programmes: EPAA data bases 3Rs research: new perspectives on safety, extended one generation study, in vitro metabolism Dissemination of 3Rs information: raising awareness, facilitating uptake of 3Rs methods, regulatory acceptance 	Simon Webb, P&G Klaus-Dieter Bremm, Bayer Phil Botham, Syngenta
11:10	Q&A	
11:20	Coffee break	
11:50	 Achievements and gaps (session 2) 3Rs in legislation: testing regulations and 3Rs incentives, acute tox, weight of evidence in REACH, GHS Validation and acceptance: data collection, streamlining validation processes, barriers to regulatory acceptance Communication: 3Rs principles, EPAA scope, EPAA activities (internal and external communication) 	Julia Scheel, Henkel Magda Chlebus, EFPIA Kati Kaskeala, Unilever
12:35	Q&A	
12: 45	Lunch	
13:35	 Discussion: Has EPAA had an Impact to date? Is EPAA making difference? What's in it for business? What motivates companies today to participate in EPAA? How to increase efficiency? EPAA future 	Bernward Garthoff, Bayer
14:50	Conclusions	Odile de Silva, L'Oreal
15:00	End of the meeting	
Final version 14 MAY 2009		

EPAA Industry Secretariat

Avenue Herrmann-Debroux 15 B, B-1160 Brussels, Belgium

e-mail: irene.manou@epaaind.eu